Details of the Drug

General Information of Drug (ID: DMBD4K3)

• Drug Name: Selinexor
• Synonyms: Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[1]
Liposarcoma	2B59	Phase 3	[2]
Neuroendocrine cancer	2B72.1	Phase 3	[2]
Acute myeloid leukaemia	2A60	Phase 2	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[4]
Diffuse large B-cell lymphoma	2A81	Phase 2	[3]
Recurrent glioblastoma	2A00.00	Phase 2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 443.3
  Logarithm of the Partition Coefficient (xlogp); 3
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 12
• Chemical Identifiers:
  Formula: C17H11F6N7O
  IUPAC Name: (Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N'-pyrazin-2-ylprop-2-enehydrazide
  Canonical SMILES: C1=CN=C(C=N1)NNC(=O)/C=C\\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
  InChI: InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-
  InChIKey: DEVSOMFAQLZNKR-RJRFIUFISA-N
• Cross-matching ID:
  PubChem CID: 71481097
  CAS Number: 1393477-72-9
  DrugBank ID: DB11942
  TTD ID: D00LNW
  INTEDE ID: DR1472
  ACDINA ID: D01420
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Exportin-1 (XPO1)	TTCJUR4	XPO1_HUMAN	Inhibitor	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[7]
Glutathione S-transferase alpha-1 (GSTA1)	DE4ZHS1	GSTA1_HUMAN	Substrate	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Bcl-2-binding component 3, isoforms 3/4 (BBC3)	OTUAXDAY	BBC3B_HUMAN	Gene/Protein Processing	[8]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[8]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Gene/Protein Processing	[8]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Gene/Protein Processing	[8]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Gene/Protein Processing	[8]
Tumor protein p73 (TP73)	OT0LUO47	P73_HUMAN	Gene/Protein Processing	[8]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Selinexor (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Selinexor and Siponimod.	Multiple sclerosis [8A40]	[9]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Selinexor and Ocrelizumab.	Multiple sclerosis [8A40]	[10]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Selinexor and Ozanimod.	Multiple sclerosis [8A40]	[11]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Selinexor 20mg tablet	20mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT04349098) Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT02025985) Phase II Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies. U.S. National Institutes of Health.
• [6] Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 August; 0: 62-73.
• [7] FDA label of Selinexor. The 2020 official website of the U.S. Food and Drug Administration.
• [8] The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression. Sci Rep. 2023 Oct 29;13(1):18554. doi: 10.1038/s41598-023-45721-z.
• [9] Cerner Multum, Inc. "Australian Product Information.".
• [10] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [11] Cerner Multum, Inc. "UK Summary of Product Characteristics.".